Last Updated: September 24, 2026

Claims for Patent: 12,527,810

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,527,810

Title:	Pharmaceutical composition, methods for treating and uses thereof
Abstract:	The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Inventor(s):	Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian BROEDL, Rolf GREMPLER
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US17/831,461
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,527,810
Patent Claims:	1. A method for improving glycemic control in an adolescent patient having type 2 diabetes mellitus, the method comprising orally administering a therapeutically effective amount of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene to the patient, wherein the adolescent patient is age 10 years to 17 years. 2. The method of claim 1, wherein 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene is administered once daily to the patient in an amount of 10 mg or 25 mg. 3. The method of claim 1, wherein the patient is an overweight patient. 4. The method of claim 1, wherein the patient is an obese patient. 5. The method of claim 2, wherein the patient has a body mass index (BMI) equal to or greater than 30 kg/m2. 6. The method of claim 1, wherein the method lowers the glycosylated hemoglobin (HbA1c) in the patient as compared to a placebo. 7. The method of claim 1, wherein the HbA1c and the fasting plasma glucose in the patient is lowered. 8. The method of claim 1, wherein the weight in the patient is lowered. 9. The method of claim 1, wherein 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene is administered once daily to the patient in an amount of 10 mg. 10. The method of claim 1, wherein 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene is administered once daily to the patient in an amount of 25 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.